{"gene":"TFE3","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2016,"finding":"TFE3 nuclear translocation in response to ER stress requires PERK kinase and calcineurin phosphatase, but is independent of mTORC1. Once nuclear, TFE3 directly transcriptionally upregulates ATF4 and other UPR genes to enhance cellular stress response.","method":"Chemical ER stressor treatment, PERK/calcineurin inhibition, nuclear translocation assays, transcriptional reporter assays in mammalian cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (pharmacological inhibition of PERK and calcineurin, nuclear localization assays, transcriptional activation assays), single lab but rigorous mechanistic dissection","pmids":["26813791"],"is_preprint":false},{"year":2021,"finding":"AMPK directly phosphorylates TFE3 on three serine residues (analogous to S466/467/469 in TFEB), which is required for TFE3 transcriptional activity upon nutrient starvation or FLCN depletion. mTORC1 controls TFE3 cytosolic retention, whereas AMPK is specifically required for TFE3 transcriptional activity — a dual and opposing regulatory mechanism.","method":"In vitro phosphorylation assays (GST pulldown with AMPK), site-directed mutagenesis (serine-to-alanine mutations), AMPK knockout/pharmacological inhibition, reporter assays in MEFs and cancer cell lines","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, multiple genetic and pharmacological validations, single lab but multiple orthogonal methods","pmids":["33734022"],"is_preprint":false},{"year":2020,"finding":"CDK4/6 interact with and phosphorylate TFE3 (and TFEB) in the nucleus, promoting their nuclear export and cytoplasmic retention, thereby inactivating lysosome biogenesis programs. During the cell cycle, lysosome numbers increase in S and G2/M phases when cyclin D turnover diminishes CDK4/6 activity.","method":"Co-immunoprecipitation, CDK4/6 chemical and genetic inactivation, nuclear/cytoplasmic fractionation, cell-cycle-stage lysosome quantification in mammalian cells","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP showing CDK4/6-TFE3 interaction, chemical and genetic perturbation with defined subcellular and functional readouts, single lab with multiple orthogonal approaches","pmids":["32662822"],"is_preprint":false},{"year":2023,"finding":"Amino acids promote recruitment of TFE3 to the lysosomal surface via Rag GTPases, activating an evolutionarily conserved phospho-degron that leads to ubiquitination by CUL1β-TrCP and proteasomal degradation of TFE3. A conserved alpha-helix in TFE3 is required for interaction with RagA. TFE3 missense mutations within the RagA-TFE3 interface cause a severe neurodevelopmental syndrome. The phospho-degron is recurrently lost in oncogenic TFE3 genomic translocations.","method":"Lysosomal fractionation, ubiquitination assays, co-immunoprecipitation with Rag GTPases, mutagenesis of degron and RagA-binding helix, proteasome inhibitor experiments in mammalian cells","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution-level biochemistry (lysosomal recruitment, ubiquitination, degron mapping), mutagenesis, and disease-variant validation in a single rigorous study","pmids":["36608670"],"is_preprint":false},{"year":2006,"finding":"TFE3 (and TFEB) directly bind to multiple cognate E-box sites in the Cd40lg promoter and are required for maximal CD40 ligand expression in activated CD4+ T cells. Combined T-cell-specific inactivation of TFE3 and TFEB results in hyper-IgM syndrome due to impaired CD40L expression, demonstrating that TFE3 and TFEB are physiologically redundant activators of Cd40lg.","method":"T-cell-specific conditional double knockout mice, EMSA/promoter binding assays, promoter-reporter assays, immunological phenotyping","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function (double KO mice), direct promoter binding demonstrated, clear immunological phenotype, rigorous in vivo and in vitro validation","pmids":["16936731"],"is_preprint":false},{"year":2019,"finding":"TFEB and TFE3 display circadian nuclear activation over the 24-h cycle and directly regulate expression of Rev-erbα (Nr1d1), a core clock repressor. Genetic ablation of TFEB and TFE3 in mice deregulates circadian autophagy gene oscillation and alters circadian wheel-running behavior. ChIP-seq cistrome analysis showed extensive overlap between TFEB/TFE3 and REV-ERBα binding sites at autophagy and metabolic genes.","method":"TFEB/TFE3 double knockout mice, ChIP-seq, RNA-seq, circadian behavioral assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mice with behavioral phenotype, ChIP-seq for direct target identification, replicated with multiple methods in vivo and in vitro","pmids":["31126958"],"is_preprint":false},{"year":2003,"finding":"The PSF-TFE3 fusion oncoprotein (arising from SFPQ-TFE3 translocation) localizes to the endosomal compartment rather than the nucleus, unlike wild-type TFE3 or PSF. PSF-TFE3 sequesters wild-type TFE3 and p53 in the extranuclear compartment, rendering them functionally null. siRNA knockdown of PSF-TFE3 in renal carcinoma cells (UOK-145) redistributes endogenous TFE3 and p53 back to the nucleus.","method":"Subcellular fractionation, immunofluorescence, siRNA knockdown in endogenous tRCC cell line (UOK-145), co-localization studies","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments plus siRNA rescue in endogenous cell line, single lab, multiple methods but no structural confirmation","pmids":["12902986"],"is_preprint":false},{"year":2007,"finding":"TFE3 strongly activates IRS-2 expression in the liver and regulates hepatic insulin signaling. TFE3 acts in synergy with Foxo1 at the IRS-2 promoter to promote insulin sensitivity, antagonizing SREBP-1c which suppresses IRS-2. TFE3 and SREBP-1c reciprocally regulate IRS-2 expression and insulin sensitivity.","method":"Promoter reporter assays, transcriptional activation experiments in hepatic cell models, genetic and biochemical interaction studies (review citing primary experimental work)","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — review paper summarizing primary experimental work on IRS-2 regulation; mechanistic details referenced from original studies but confidence limited by review format","pmids":["17279346"],"is_preprint":false},{"year":2019,"finding":"Loss of FLCN leads to increased nuclear TFE3, which suppresses canonical WNT signaling. Silencing TFE3 in FLCN-deficient cells completely reversed the decreased WNT pathway activity phenotype, placing TFE3 downstream of FLCN and upstream of WNT in lung fibroblasts.","method":"Flcn knockout in MEFs and human fetal lung fibroblasts (MRC-5), RNA-seq, TCF/LEF reporter assays, TFE3 siRNA rescue experiments","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (FLCN KO + TFE3 silencing rescue), TCF/LEF reporter readout, single lab","pmids":["31272105"],"is_preprint":false},{"year":2021,"finding":"VPS41 loss of function causes cytosolic redistribution of mTORC1, leading to constitutive nuclear localization of TFE3 and enhanced LC3-II levels, but with a reduced autophagic response to nutrient starvation, demonstrating that HOPS complex-mediated lysosomal function is required for proper mTORC1-dependent TFE3 regulation.","method":"Patient fibroblasts with compound heterozygous VPS41 mutations, VPS41 siRNA in HeLa cells, subcellular fractionation, mTORC1 substrate phosphorylation assays","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived fibroblasts and siRNA knockdown with nuclear localization and mTORC1 substrate readouts, single study","pmids":["33851776"],"is_preprint":false},{"year":2023,"finding":"TFEB and TFE3 interact with the FACT histone chaperone complex (SSRP1/SUPT16H). This interaction is induced by nuclear translocation of TFEB/TFE3 upon nutrient deprivation or oxidative stress. FACT depletion or inhibition (curaxin) severely impairs induction of antioxidant and lysosomal gene targets without affecting TFEB activation, stability, or promoter binding, demonstrating that FACT chromatin remodeling is required for efficient TFE3 transcriptional output.","method":"Co-immunoprecipitation of TFEB/TFE3 with SSRP1/SUPT16H, siRNA depletion of FACT components, curaxin pharmacological inhibition, ChIP assays, gene expression profiling","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, siRNA depletion, and pharmacological inhibition with defined transcriptional readouts; single lab","pmids":["35230915"],"is_preprint":false},{"year":2023,"finding":"TRIM28 promotes ubiquitination and proteasome-mediated degradation of TFE3, restraining TFE3-dependent autophagic gene expression in kidney cancer cells. TFE3 interacts with and recruits the histone H3K27 demethylase KDM6A to autophagic gene promoters; KDM6A increases H3K4me3 (rather than demethylating H3K27) at TFE3 target genes to upregulate their expression.","method":"Co-immunoprecipitation (TFE3-KDM6A), ubiquitination assays, TRIM28 knockdown/overexpression, histone modification ChIP, proliferation assays in kidney cancer cell lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, ChIP for histone marks, genetic perturbation; single lab with multiple methods","pmids":["36935008"],"is_preprint":false},{"year":2021,"finding":"Both TFEB and TFE3 are substrates of PLK4 (polo-like kinase 4). Centrosome depletion inactivates PLK4, resulting in TFEB/TFE3 dephosphorylation and nuclear translocation with transcriptional activation of autophagy and lysosome genes, supporting acentrosomal cancer cell proliferation.","method":"PLK4 knockout/inhibition, biochemical phosphorylation assays, nuclear translocation imaging, genetic epistasis with TFEB/TFE3 double KO in cancer cells","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical substrate identification, genetic epistasis with double KO, single lab","pmids":["35316161"],"is_preprint":false},{"year":2023,"finding":"EIF2S1 (eIF2α) phosphorylation is required for nuclear translocation of TFE3 during ER stress. PPP3/calcineurin-mediated dephosphorylation and YWHA/14-3-3 dissociation are required but insufficient for nuclear retention of TFE3 during ER stress; EIF2AK3/PERK is upstream of this pathway. Overexpression of active ATF6 or XBP1s/ATF4 differentially rescues TFE3 nuclear translocation defects in eIF2α phosphorylation-deficient cells.","method":"EIF2S1 phosphorylation-deficient (S51A) cells, nuclear translocation assays, calcineurin and 14-3-3 dissociation experiments, adenoviral overexpression of UPR effectors, autophagy flux assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (knock-in phospho-deficient cells) plus pharmacological dissection, multiple UPR branch rescue experiments, single lab","pmids":["36719671"],"is_preprint":false},{"year":2024,"finding":"mTORC1 restricts TFE3 activity through an auto-regulatory negative feedback: activated mTOR mutants display low lysosome occupancy due to release of mTORC1 from lysosomes dependent on its own kinase activity, causing hypo-phosphorylation and nuclear accumulation of TFE3. Rheb-activated mTORC1 does not increase cytoplasmic/lysosomal mTORC1 ratio, indicating the existence of distinct mTORC1 pools with different substrate specificity toward TFE3.","method":"Activated mTOR mutant cell lines, lysosomal fractionation, TFE3 nuclear localization assays, Rheb overexpression experiments in human cells","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lysosomal fractionation and nuclear localization with activated kinase mutants, single lab","pmids":["39486419"],"is_preprint":false},{"year":2024,"finding":"TMEM55B sequesters the FLCN/FNIP complex at lysosomes in response to oxidative stress, thereby facilitating TFE3 nuclear translocation and transcriptional activation of stress-response genes. tmem55 knockout zebrafish show increased susceptibility to oxidative stress, confirming in vivo relevance.","method":"Co-immunoprecipitation (TMEM55B-FLCN/FNIP), TFE3 nuclear translocation assays, TMEM55B knockout zebrafish model, arsenite stress experiments","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, nuclear translocation assays, in vivo zebrafish KO; multiple methods but primarily single lab","pmids":["38168055"],"is_preprint":false},{"year":2016,"finding":"The ASPL-TFE3 (ASPSCR1-TFE3) fusion oncoprotein directly activates transcription of p21 (CDKN1A) in a p53-independent manner through binding to the p21 promoter region, causing cell cycle arrest and cellular senescence in mesenchymal stem cells.","method":"Ectopic expression of ASPL-TFE3 in 293 cells and tetracycline-inducible mesenchymal stem cells, p21 promoter luciferase reporter, RT-PCR, senescence-associated β-galactosidase assay, p21 siRNA epistasis","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay plus siRNA epistasis confirming p21-dependent senescence, single lab","pmids":["27673450"],"is_preprint":false},{"year":2021,"finding":"TAZ-CAMTA1 and YAP-TFE3 fusion oncoproteins both interact with YEATS2 and ZZZ3 (components of the ATAC histone acetyltransferase complex) despite dissimilarity of their C-terminal fusion partners. This interaction drives a unique transcriptome by hyperactivating TEAD-based transcription and modulating chromatin via the ATAC complex.","method":"Combined proteomic/genetic screen (Co-IP/MS), integrative ChIP-seq and RNA-seq in human and murine cell lines expressing fusion proteins","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-confirmed Co-IP interaction, integrated ChIP-seq/RNA-seq, single study but multiple orthogonal methods","pmids":["33913810"],"is_preprint":false},{"year":2020,"finding":"PRCC-TFE3 fusion protein, constitutively localized in the nucleus, transcriptionally activates the E3 ubiquitin ligase PRKN/parkin, driving PINK1-PRKN-dependent mitophagy that promotes tRCC cell survival under mitochondrial oxidative damage and cell proliferation by decreasing mitochondrial ROS. PRCC-TFE3 also activates PPARGC1A/PGC1α-NRF1 to accelerate mitochondrial biogenesis.","method":"Nuclear localization studies of PRCC-TFE3, ChIP/reporter assays for PRKN promoter, mitophagy flux assays, ROS measurement, proliferation assays in PRCC-TFE3 tRCC cell lines","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter activation, mitophagy flux assays, and ROS measurements in fusion-expressing cells; single lab","pmids":["33019842"],"is_preprint":false},{"year":2020,"finding":"PRCC-TFE3 fusion positively regulates expression of dynamin-related protein 1 (Drp1) and fission protein 1 (Fis1), altering mitochondrial distribution and promoting cell migration and invasion independently of MMP-2/MMP-9 in tRCC cells.","method":"PRCC-TFE3 expression in tRCC cell lines, Drp1/Fis1 Western blot and RT-PCR, mitochondrial distribution imaging, migration/invasion assays","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single set of methods without mechanistic dissection of how PRCC-TFE3 regulates Drp1","pmids":["32339358"],"is_preprint":false},{"year":2018,"finding":"TFE3 chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) in a SFPQ-TFE3 tRCC patient-derived xenograft showed strong enrichment for PI3K/AKT/mTOR pathway genes as direct transcriptional targets. TFE3 knockdown decreased IRS-1 expression, linking TFE3 to IRS-1/PI3K/mTOR signaling in translocation RCC.","method":"TFE3 ChIP-seq in PDX model, TFE3 siRNA knockdown, phospho-S6 and phospho-4EBP1 Western blot","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq for direct target identification plus siRNA knockdown with pathway readout; single lab, patient-derived xenograft model","pmids":["30061365"],"is_preprint":false},{"year":2023,"finding":"TFEB and TFE3 translocate to the nucleus in response to beta-coronavirus infection via a calcineurin-dependent mechanism, and bind to promoters of multiple lysosomal and immune genes. TFE3/TFEB depletion significantly decreases MHV-induced upregulation of immune regulators, and overexpression of either factor increases cytokine/chemokine expression. TFEB/TFE3 also modulate type I IFN signaling by controlling IRF3 activation.","method":"Beta-coronavirus infection of macrophages, TFEB/TFE3 nuclear translocation assays, calcineurin inhibition, TFEB/TFE3 siRNA depletion, promoter ChIP, gene expression analysis","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for promoter binding, siRNA depletion with gene expression readout, calcineurin pharmacological dissection; single lab","pmids":["36785787"],"is_preprint":false},{"year":2021,"finding":"NUPR1 maintains autophagic flux and lysosomal function by directly increasing TFE3 transcriptional activity. NUPR1 knockdown in OSCC cells reduces TFE3 activity, impairing autophagy and decreasing cancer cell proliferation and metastasis in vitro and in vivo.","method":"Quantitative proteomics (TMT-based), NUPR1 stable knockdown, TFE3 activity reporter assays, in vitro and in vivo proliferation/metastasis assays","journal":"Signal transduction and targeted therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — NUPR1-TFE3 axis defined by proteomic screen and knockdown with activity readout, but direct molecular mechanism of NUPR1-TFE3 interaction not fully established","pmids":["35462576"],"is_preprint":false},{"year":2024,"finding":"ASPSCR1::TFE3 interacts with VCP/p97 (AAA+ ATPase), which co-distributes with the fusion protein across chromatin at enhancers genome-wide. VCP hexameric assembly and enzymatic activity are required for the oncogenic transcriptional signature of ASPSCR1::TFE3, and both proteins are co-dependent for cancer cell proliferation and tumorigenesis in vitro and in mouse models of ASPS and RCC.","method":"Co-immunoprecipitation/MS (nuclear complex proteomics), ChIP-seq for ASPSCR1::TFE3 and VCP co-occupancy, HiChIP chromatin conformation, VCP ATPase mutants, in vivo mouse tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — MS-confirmed Co-IP, ChIP-seq co-occupancy, HiChIP chromatin conformation, enzymatic mutants, and in vivo epistasis; multiple orthogonal methods in a single rigorous study","pmids":["38326311"],"is_preprint":false},{"year":2023,"finding":"ASPSCR1::TFE3 drives ASPS by regulating transcriptional programs controlling angiogenesis through super-enhancer (SE) modulation. Loss of ASPSCR1::TFE3 expression induces SE redistribution at angiogenesis genes. Epigenomic CRISPR/dCas9 screening identifies Pdgfb, Rab27a, Sytl2, and Vwf as critical angiogenesis targets of ASPSCR1::TFE3 via SE activity. ASPSCR1::TFE3 is dispensable for in vitro tumor maintenance but required for in vivo tumor development via angiogenesis.","method":"ASPSCR1::TFE3 inducible expression/depletion, H3K27ac ChIP-seq for SE mapping, CRISPR/dCas9 epigenomic screen, in vivo tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq SE mapping, CRISPR functional screen, and in vivo validation; multiple orthogonal methods in single rigorous study","pmids":["37029109"],"is_preprint":false},{"year":2024,"finding":"ASPSCR1::TFE3 directly interacts with key epigenetic regulators at enhancers and promoters. Among effector programs, it drives cyclin D1 expression to support cell proliferation. Disruption of cyclin D1/CDK4 signaling impairs ASPS proliferative capacity.","method":"ChIP-seq, transcriptome profiling of ASPS tumors and preclinical models, CDK4/6 inhibitor treatment, CDK4/6 + anti-angiogenesis combination in xenografts","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq interaction at enhancers, pharmacological epistasis, in vivo xenograft validation; single lab","pmids":["38657118"],"is_preprint":false},{"year":2021,"finding":"NONO-TFE3 fusion protein directly transcriptionally activates HIF1A expression (confirmed by ChIP and luciferase reporter assay), promoting aerobic glycolysis and angiogenesis under hypoxia in NONO-TFE3 tRCC.","method":"ChIP assay, luciferase reporter assay, RT-qPCR, glycolysis/lactate measurements, tube formation and migration assays in UOK109 cells (NONO-TFE3 tRCC)","journal":"Current cancer drug targets","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP + reporter assay for direct target activation, functional metabolic readouts; single lab","pmids":["33845743"],"is_preprint":false},{"year":2024,"finding":"TFE3 splicing-factor (TFE3-SF) fusion proteins (e.g., SFPQ-TFE3, NONO-TFE3) drive oncogenic transformation through both transcriptional and RNA splicing activities, differentially altering the transcriptome and splicing landscape in a fusion-partner-dependent manner. Inhibiting TFE3-SF dimerization reverses oncogenic activity.","method":"In silico structure prediction, transcriptome and splicing profiling, FRET-based dimerization assay, HTHCS of FDA-approved drug library, 2D/3D PDX validation models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET dimerization assay, transcriptome/splicing profiling, PDX validation; multiple methods but partially computational","pmids":["38266162"],"is_preprint":false},{"year":2025,"finding":"TFE3 gene fusions transcriptionally rewire translocation RCC toward oxidative phosphorylation (OXPHOS), creating dependence on NADH reductive stress management. Genome-scale CRISPR screening identified EGLN1 (PHD2) as a TFE3 fusion-selective vulnerability; EGLN1 inhibition stabilizes HIF-1α and reprograms metabolism away from OXPHOS, suppressing tRCC growth.","method":"Genome-scale CRISPR screen, transcriptome profiling, metabolic flux assays (OXPHOS measurement), EGLN1 genetic/pharmacological inhibition in tRCC cell lines and in vivo models","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-scale CRISPR screen, metabolic profiling, and in vivo validation; multiple orthogonal methods establishing TFE3-driven OXPHOS mechanism","pmids":["39915638"],"is_preprint":false},{"year":2025,"finding":"TFE3 drives the mesenchymal/invasive phenotype in melanoma. MITF directly or indirectly activates expression of FNIP1, FNIP2, and FLCN (non-canonical mTORC1 pathway components), which promote cytoplasmic retention and lysosome-mediated degradation of TFE3, thereby suppressing the mesenchymal state. Deletion of TFE3 in MITF-low melanoma cells suppresses migration and metastasis.","method":"TFE3 deletion in MITF-low melanoma cell lines, FLCN/FNIP1/FNIP2 overexpression, subcellular fractionation, in vitro migration and in vivo metastasis assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deletion with migratory/metastatic phenotype, pathway epistasis via FLCN/FNIP expression; single lab","pmids":["40138313"],"is_preprint":false},{"year":2023,"finding":"FLCN acts as a negative regulator of TFE3 (and TFEB) by enabling their phosphorylation by mTORC1. Both Tfeb and Tfe3 contribute in a differential and cooperative manner to kidney cystogenesis in Flcn KO mice. Silencing either TFE3 or TFEB rescues tumorigenesis in human BHD renal tumor cell line-derived xenografts.","method":"Flcn/Tfeb/Tfe3 double and triple KO mice, BHD patient-derived tumor analysis, xenograft rescue experiments with TFE3/TFEB silencing","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — triple KO genetic epistasis in mice, patient-derived tumor analysis, and xenograft rescue; multiple in vivo models","pmids":["36987696"],"is_preprint":false},{"year":2024,"finding":"WWTR1::TFE3 fusion protein promotes colony formation in soft agar (oncogenic transformation). The TEAD-binding domain of WWTR1 in the fusion is required for this transformative effect, as mutation of the WWTR1 domain to inhibit TEAD binding abrogates WWTR1::TFE3-driven transformation.","method":"Soft agar colony formation assay in NIH3T3 cells, TEAD-binding domain mutagenesis, targeted RNA-seq for fusion identification","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro transformation assay with mutagenesis of functional domain; single case report with in vitro mechanistic follow-up","pmids":["38380774"],"is_preprint":false},{"year":2021,"finding":"NRF-1 (Nuclear Respiratory Factor 1) directly binds to the promoter region of TFE3 and transcriptionally activates TFE3 expression. NRF-1 knockdown reduces TFE3 levels, inhibits mTOR pathway activation (phospho-AKT, phospho-S6), blocks cell cycle progression, and reduces mitochondrial biogenesis; TFE3 overexpression rescues these effects.","method":"Luciferase promoter reporter assay, ChIP of NRF-1 at TFE3 promoter, shRNA knockdown, TFE3 rescue overexpression, flow cytometry cell cycle analysis in 786-O and 293T cells","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP + promoter reporter for direct transcriptional regulation, genetic rescue; single lab","pmids":["34345304"],"is_preprint":false}],"current_model":"TFE3 is a bHLH-LZ transcription factor whose activity is primarily controlled by subcellular localization: under nutrient-replete conditions, Rag GTPases recruit TFE3 to the lysosomal surface where mTORC1 phosphorylates it, promoting cytoplasmic retention via 14-3-3 binding and also targeting it for CUL1β-TrCP-mediated ubiquitination and proteasomal degradation via a conserved phospho-degron; upon starvation, AMPK phosphorylates TFE3 on distinct serine residues to license transcriptional activity, while calcineurin-mediated dephosphorylation and 14-3-3 dissociation enable nuclear translocation; in the nucleus, TFE3 activates the CLEAR gene network (lysosomal biogenesis, autophagy) and additional programs including ATF4/UPR genes, IRS-2 (hepatic insulin signaling), CD40L (T-cell immunity), Rev-erbα (circadian clock), and HIF1A/PRKN (in fusion contexts), often requiring cofactors such as the FACT histone chaperone complex; oncogenic chromosomal translocations (e.g., ASPSCR1::TFE3, PRCC-TFE3, SFPQ-TFE3, NONO-TFE3) constitutively localize TFE3 to the nucleus by bypassing mTORC1/Rag-dependent regulation, driving transcriptional rewiring toward OXPHOS, angiogenesis, and other tumor-promoting programs, with ASPSCR1::TFE3 additionally recruiting VCP/p97 as an obligate co-factor to organize enhancer loops."},"narrative":{"mechanistic_narrative":"TFE3 is a basic helix-loop-helix transcription factor that couples nutrient, stress, and cell-cycle signals to the activation of lysosomal, autophagic, and metabolic gene programs through tightly regulated nucleocytoplasmic shuttling [PMID:36608670, PMID:39486419]. Under nutrient-replete conditions, amino acids drive Rag-GTPase-dependent recruitment of TFE3 to the lysosomal surface via a conserved alpha-helix that contacts RagA, where an evolutionarily conserved phospho-degron triggers CUL1β-TrCP-mediated ubiquitination and proteasomal degradation; missense mutations at the RagA-TFE3 interface cause a severe neurodevelopmental syndrome, and this phospho-degron is recurrently lost in oncogenic TFE3 translocations [PMID:36608670]. mTORC1 enforces cytoplasmic retention, with an autoregulatory feedback in which active mTOR releases from lysosomes to permit TFE3 nuclear accumulation [PMID:39486419], while FLCN promotes mTORC1-dependent phosphorylation as a negative regulator [PMID:36987696]. Diverse signals license nuclear entry: AMPK directly phosphorylates three serines required for transcriptional activity upon starvation [PMID:33734022]; PERK/eIF2α signaling and calcineurin-mediated dephosphorylation with 14-3-3 dissociation drive translocation during ER and oxidative stress, including TMEM55B-dependent sequestration of FLCN/FNIP at lysosomes [PMID:26813791, PMID:36719671, PMID:38168055]; and CDK4/6 and PLK4 phosphorylation restrain nuclear activity to gate lysosome biogenesis with the cell cycle and centrosome status [PMID:32662822, PMID:35316161]. In the nucleus, TFE3 requires the FACT histone chaperone complex (SSRP1/SUPT16H) and recruits the H3K27 demethylase KDM6A for efficient transcriptional output, and is destabilized by TRIM28-mediated ubiquitination [PMID:35230915, PMID:36935008]. Beyond the CLEAR/autophagy network, TFE3 activates ATF4/UPR genes [PMID:26813791], IRS-2 in hepatic insulin signaling in synergy with Foxo1 [PMID:17279346], Cd40lg in CD4+ T cells (redundantly with TFEB, with double loss causing hyper-IgM syndrome) [PMID:16936731], Rev-erbα in the circadian clock [PMID:31126958], and immune/interferon genes during coronavirus infection [PMID:36785787]. Oncogenic chromosomal translocations fuse TFE3 to partners such as ASPSCR1, PRCC, SFPQ, NONO, and WWTR1, bypassing mTORC1/Rag regulation to constitutively localize the fusion to the nucleus and rewire transcription toward OXPHOS, angiogenesis, and mitochondrial programs; ASPSCR1::TFE3 obligately recruits the AAA+ ATPase VCP/p97 to organize enhancer loops driving its oncogenic signature [PMID:38326311, PMID:37029109, PMID:39915638].","teleology":[{"year":2006,"claim":"Established that TFE3 has a physiological role beyond lysosomal biology by demonstrating it directly drives CD40 ligand expression in T cells, redundantly with TFEB.","evidence":"T-cell-specific conditional double knockout mice, EMSA/promoter binding, and reporter assays","pmids":["16936731"],"confidence":"High","gaps":["Does not define how TFE3 nuclear activity is regulated in T cells","Functional redundancy with TFEB obscures TFE3-specific contributions"]},{"year":2003,"claim":"Showed that an oncogenic TFE3 fusion can act through mislocalization, with PSF-TFE3 sequestering wild-type TFE3 and p53 in an extranuclear compartment.","evidence":"Subcellular fractionation, immunofluorescence, and siRNA rescue in an endogenous tRCC cell line","pmids":["12902986"],"confidence":"Medium","gaps":["No structural basis for the abnormal localization","Contrasts with later fusions that are constitutively nuclear, indicating fusion-partner-specific behavior"]},{"year":2007,"claim":"Linked TFE3 to systemic metabolism by identifying IRS-2 as a hepatic target whose activation promotes insulin sensitivity.","evidence":"Promoter reporter and transcriptional interaction studies in hepatic models (review of primary work)","pmids":["17279346"],"confidence":"Medium","gaps":["Review format limits primary-data resolution","Mechanism of Foxo1/SREBP-1c antagonism at the IRS-2 promoter not fully dissected"]},{"year":2016,"claim":"Defined a stress-responsive, mTORC1-independent activation route, showing PERK and calcineurin drive TFE3 nuclear entry to upregulate ATF4/UPR genes.","evidence":"Pharmacological PERK/calcineurin inhibition with nuclear translocation and reporter assays","pmids":["26813791"],"confidence":"High","gaps":["Phosphosites controlling ER-stress translocation not mapped","Relationship to nutrient-sensing pathway unresolved at this stage"]},{"year":2016,"claim":"Showed that an oncogenic fusion can paradoxically induce growth arrest, with ASPL-TFE3 transactivating p21 to trigger p53-independent senescence in mesenchymal cells.","evidence":"Ectopic and inducible fusion expression, p21 promoter reporter, senescence assays, and p21 siRNA epistasis","pmids":["27673450"],"confidence":"Medium","gaps":["Context-dependence of arrest vs transformation unexplained","Direct promoter occupancy at endogenous loci not shown"]},{"year":2018,"claim":"Identified PI3K/AKT/mTOR pathway genes including IRS-1 as direct fusion targets, linking TFE3 translocation RCC to feed-forward growth signaling.","evidence":"TFE3 ChIP-seq in an SFPQ-TFE3 PDX with siRNA knockdown and pathway phospho-readouts","pmids":["30061365"],"confidence":"Medium","gaps":["Single PDX model","Causal contribution of each target to tumor growth not isolated"]},{"year":2019,"claim":"Placed TFE3 within circadian and developmental signaling networks via direct regulation of Rev-erbα and as a downstream effector of FLCN suppressing WNT signaling.","evidence":"TFEB/TFE3 double KO mice with ChIP-seq and behavioral assays; FLCN KO with TCF/LEF reporters and TFE3 rescue","pmids":["31126958","31272105"],"confidence":"High","gaps":["Direct vs indirect mechanism of WNT suppression unclear","TFE3-specific cistrome separable from TFEB only partially defined"]},{"year":2020,"claim":"Revealed cell-cycle and fusion-driven metabolic control: CDK4/6 phosphorylate TFE3 to enforce nuclear export, while PRCC-TFE3 activates PRKN-driven mitophagy and mitochondrial fission programs.","evidence":"Reciprocal Co-IP and CDK4/6 perturbation; promoter/ChIP and mitophagy/ROS assays in PRCC-TFE3 tRCC lines","pmids":["32662822","33019842","32339358"],"confidence":"Medium","gaps":["CDK4/6 phosphosites on TFE3 not mapped","Drp1/Fis1 regulation lacks mechanistic dissection (Low confidence)","Direct vs indirect fission-gene activation unresolved"]},{"year":2021,"claim":"Established a dual, opposing kinase logic (AMPK activating, mTORC1 retaining) and identified PLK4 and additional regulators (NRF-1, NUPR1, VPS41/HOPS) controlling TFE3 abundance and localization.","evidence":"In vitro AMPK kinase assays with serine mutants; PLK4 perturbation; NRF-1 ChIP/reporter; NUPR1 proteomics/knockdown; VPS41 patient fibroblasts","pmids":["33734022","35316161","34345304","35462576","33851776"],"confidence":"Medium","gaps":["NUPR1-TFE3 direct interaction not established (Low confidence)","Whether AMPK and PLK4 act on overlapping or distinct sites unclear","Integration of multiple regulators into one kinetic model lacking"]},{"year":2021,"claim":"Showed convergent enhancer-machinery hijacking and metabolic rewiring by fusions: YAP-TFE3 engages the ATAC HAT complex, and NONO-TFE3 directly activates HIF1A to drive glycolysis and angiogenesis.","evidence":"Co-IP/MS and integrated ChIP-seq/RNA-seq for YAP-TFE3; ChIP and reporter with metabolic assays for NONO-TFE3","pmids":["33913810","33845743"],"confidence":"Medium","gaps":["Fusion-partner-specific cofactor requirements not generalized","Single cell-line models for metabolic readouts"]},{"year":2023,"claim":"Resolved the central nutrient-degradation mechanism: Rag-GTPase recruitment activates a conserved phospho-degron for CUL1β-TrCP-mediated turnover, with disease variants and translocations both disrupting this control.","evidence":"Lysosomal fractionation, ubiquitination assays, RagA Co-IP, degron/helix mutagenesis, and disease-variant validation","pmids":["36608670"],"confidence":"High","gaps":["Kinase generating the degron phosphorylation not fully defined","How fusion loss of degron quantitatively elevates nuclear TFE3 not measured"]},{"year":2023,"claim":"Defined the nuclear transcriptional machinery and stress inputs: FACT chromatin remodeling and KDM6A recruitment are required for output, TRIM28 limits TFE3 levels, eIF2α phosphorylation and TMEM55B-FLCN/FNIP sequestration gate stress translocation, and FLCN licenses mTORC1-dependent phosphorylation in vivo.","evidence":"Co-IP, siRNA/curaxin, ubiquitination and histone-mark ChIP; phospho-deficient eIF2α cells; TMEM55B KO zebrafish; Flcn/Tfeb/Tfe3 KO mice and xenograft rescue","pmids":["35230915","36935008","36719671","38168055","36987696"],"confidence":"High","gaps":["Order of FACT vs KDM6A recruitment at target promoters unclear","How distinct stress kinases converge on the same translocation machinery not unified"]},{"year":2023,"claim":"Showed ASPSCR1::TFE3 governs in vivo tumorigenesis through super-enhancer-driven angiogenesis programs rather than autonomous proliferation.","evidence":"Inducible fusion depletion, H3K27ac ChIP-seq, CRISPR/dCas9 epigenomic screen, and in vivo tumor models","pmids":["37029109"],"confidence":"High","gaps":["Cofactors organizing the super-enhancers not yet identified at this stage","In vitro vs in vivo dependence discrepancy mechanistically unexplained"]},{"year":2024,"claim":"Identified VCP/p97 as an obligate ASPSCR1::TFE3 cofactor organizing enhancer chromatin, and clarified mTORC1 pool-specific feedback controlling wild-type TFE3 localization.","evidence":"Co-IP/MS, ChIP-seq co-occupancy, HiChIP, VCP ATPase mutants, and in vivo epistasis; activated mTOR mutants with lysosomal fractionation","pmids":["38326311","39486419"],"confidence":"High","gaps":["Molecular basis of distinct mTORC1 pool substrate specificity unresolved","How VCP ATPase activity mechanically organizes enhancer loops not defined"]},{"year":2024,"claim":"Extended fusion biology to dual transcription/splicing activity and cyclin D1-driven proliferation, and established WWTR1::TFE3 transformation as TEAD-binding-dependent.","evidence":"FRET dimerization, transcriptome/splicing profiling, PDX validation; ChIP-seq and CDK4/6 inhibition; soft agar assay with TEAD-domain mutagenesis","pmids":["38266162","38657118","38380774"],"confidence":"Medium","gaps":["Relative contribution of splicing vs transcription to transformation not quantified","WWTR1::TFE3 in vivo relevance from single case"]},{"year":2025,"claim":"Defined a TFE3-fusion-selective metabolic vulnerability (OXPHOS dependence and EGLN1) and a role for TFE3 in driving the mesenchymal/invasive melanoma state downstream of MITF-FLCN/FNIP control.","evidence":"Genome-scale CRISPR screen with metabolic flux and EGLN1 inhibition in tRCC; TFE3 deletion and FLCN/FNIP epistasis in MITF-low melanoma","pmids":["39915638","40138313"],"confidence":"High","gaps":["How the same OXPHOS rewiring generalizes across fusion partners not fully tested","Melanoma TFE3 target genes driving invasion not enumerated"]},{"year":null,"claim":"It remains unresolved how the multiple upstream kinases (mTORC1, AMPK, CDK4/6, PLK4, PERK/eIF2α) and phosphatases are integrated into a single quantitative model of TFE3 phosphosite occupancy that dictates localization, stability, and target-gene selectivity.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Complete TFE3 phosphosite map across conditions lacking","Rules determining which target programs (CLEAR vs UPR vs metabolic) are selected not defined","Structural basis of fusion-driven enhancer cofactor recruitment incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,5,7,26,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,5,16,26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,3,13,14,23]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3,14]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[3,14,15]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[1,5,10,11,12,18,22,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,7,16,26]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,13,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,18,23,24,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,8,14,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,21]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[5]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,11,23,24]}],"complexes":[],"partners":["RAGA","VCP","SSRP1","SUPT16H","KDM6A","TRIM28","FLCN","FOXO1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19532","full_name":"Transcription factor E3","aliases":["Class E basic helix-loop-helix protein 33","bHLHe33"],"length_aa":575,"mass_kda":61.5,"function":"Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response (PubMed:2338243, PubMed:24448649, PubMed:29146937, PubMed:30733432, PubMed:31672913, PubMed:37079666). Specifically recognizes and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF (PubMed:24448649). Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFE3 phosphorylation by MTOR promotes its inactivation (PubMed:24448649, PubMed:31672913, PubMed:36608670). Upon starvation or lysosomal stress, inhibition of MTOR induces TFE3 dephosphorylation, resulting in transcription factor activity (PubMed:24448649, PubMed:31672913, PubMed:36608670). Specifically recognizes and binds the CLEAR-box sequence (5'-GTCACGTGAC-3') present in the regulatory region of many lysosomal genes, leading to activate their expression, thereby playing a central role in expression of lysosomal genes (PubMed:24448649). Maintains the pluripotent state of embryonic stem cells by promoting the expression of genes such as ESRRB; mTOR-dependent TFE3 cytosolic retention and inactivation promotes exit from pluripotency (By similarity). Required to maintain the naive pluripotent state of hematopoietic stem cell; mTOR-dependent cytoplasmic retention of TFE3 promotes the exit of hematopoietic stem cell from pluripotency (PubMed:30733432). TFE3 activity is also involved in the inhibition of neuronal progenitor differentiation (By similarity). Acts as a positive regulator of browning of adipose tissue by promoting expression of target genes; mTOR-dependent phosphorylation promotes cytoplasmic retention of TFE3 and inhibits browning of adipose tissue (By similarity). In association with TFEB, activates the expression of CD40L in T-cells, thereby playing a role in T-cell-dependent antibody responses in activated CD4(+) T-cells and thymus-dependent humoral immunity (By similarity). Specifically recognizes the MUE3 box, a subset of E-boxes, present in the immunoglobulin enhancer (PubMed:2338243). It also binds very well to a USF/MLTF site (PubMed:2338243). Promotes TGF-beta-induced transcription of COL1A2; via its interaction with TSC22D1 at E-boxes in the gene proximal promoter (By similarity). May regulate lysosomal positioning in response to nutrient deprivation by promoting the expression of PIP4P1 (PubMed:29146937)","subcellular_location":"Cytoplasm, cytosol; Nucleus; Lysosome membrane","url":"https://www.uniprot.org/uniprotkb/P19532/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFE3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TFE3","total_profiled":1310},"omim":[{"mim_id":"619389","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 29; SCAR29","url":"https://www.omim.org/entry/619389"},{"mim_id":"608268","title":"RAS-RELATED GTP-BINDING PROTEIN D; RRAGD","url":"https://www.omim.org/entry/608268"},{"mim_id":"607273","title":"FOLLICULIN; FLCN","url":"https://www.omim.org/entry/607273"},{"mim_id":"606243","title":"ALVEOLAR SOFT PART SARCOMA; ASPS","url":"https://www.omim.org/entry/606243"},{"mim_id":"606236","title":"ASPSCR1 TETHER FOR SLC2A4, UBX DOMAIN-CONTAINING; ASPSCR1","url":"https://www.omim.org/entry/606236"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TFE3"},"hgnc":{"alias_symbol":["TFEA","bHLHe33"],"prev_symbol":[]},"alphafold":{"accession":"P19532","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19532","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19532-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19532-F1-predicted_aligned_error_v6.png","plddt_mean":58.66},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFE3","jax_strain_url":"https://www.jax.org/strain/search?query=TFE3"},"sequence":{"accession":"P19532","fasta_url":"https://rest.uniprot.org/uniprotkb/P19532.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19532/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19532"}},"corpus_meta":[{"pmid":"27298091","id":"PMC_27298091","title":"TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress.","date":"2016","source":"Annual review of cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27298091","citation_count":353,"is_preprint":false},{"pmid":"26813791","id":"PMC_26813791","title":"TFEB and TFE3 are novel components of the integrated stress response.","date":"2016","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26813791","citation_count":258,"is_preprint":false},{"pmid":"25048860","id":"PMC_25048860","title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.","date":"2014","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/25048860","citation_count":257,"is_preprint":false},{"pmid":"33734022","id":"PMC_33734022","title":"AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33734022","citation_count":192,"is_preprint":false},{"pmid":"34489456","id":"PMC_34489456","title":"Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34489456","citation_count":121,"is_preprint":false},{"pmid":"21602817","id":"PMC_21602817","title":"Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/21602817","citation_count":111,"is_preprint":false},{"pmid":"35462576","id":"PMC_35462576","title":"NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35462576","citation_count":102,"is_preprint":false},{"pmid":"15050900","id":"PMC_15050900","title":"Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function.","date":"2004","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15050900","citation_count":89,"is_preprint":false},{"pmid":"32662822","id":"PMC_32662822","title":"CDK4/6 regulate lysosome biogenesis through TFEB/TFE3.","date":"2020","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32662822","citation_count":88,"is_preprint":false},{"pmid":"30061365","id":"PMC_30061365","title":"Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30061365","citation_count":78,"is_preprint":false},{"pmid":"16936731","id":"PMC_16936731","title":"Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16936731","citation_count":76,"is_preprint":false},{"pmid":"30622287","id":"PMC_30622287","title":"NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30622287","citation_count":74,"is_preprint":false},{"pmid":"31126958","id":"PMC_31126958","title":"Nutrient-sensitive transcription factors TFEB and TFE3 couple autophagy and metabolism to the peripheral clock.","date":"2019","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/31126958","citation_count":66,"is_preprint":false},{"pmid":"34381186","id":"PMC_34381186","title":"YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/34381186","citation_count":59,"is_preprint":false},{"pmid":"33913810","id":"PMC_33913810","title":"TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33913810","citation_count":57,"is_preprint":false},{"pmid":"38597260","id":"PMC_38597260","title":"TFE3 -Rearranged PEComa/PEComa-like Neoplasms : Report of 25 New Cases Expanding the Clinicopathologic Spectrum and Highlighting its Association With Prior Exposure to Chemotherapy.","date":"2024","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38597260","citation_count":55,"is_preprint":false},{"pmid":"34131293","id":"PMC_34131293","title":"Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/34131293","citation_count":47,"is_preprint":false},{"pmid":"31347689","id":"PMC_31347689","title":"TFEA.ChIP: a tool kit for transcription factor binding site enrichment analysis capitalizing on ChIP-seq datasets.","date":"2019","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31347689","citation_count":46,"is_preprint":false},{"pmid":"33899786","id":"PMC_33899786","title":"Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung.","date":"2021","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33899786","citation_count":45,"is_preprint":false},{"pmid":"34079046","id":"PMC_34079046","title":"Transcription factor enrichment analysis (TFEA) quantifies the activity of multiple transcription factors from a single experiment.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34079046","citation_count":44,"is_preprint":false},{"pmid":"36987696","id":"PMC_36987696","title":"TFEB and TFE3 drive kidney cystogenesis and tumorigenesis.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36987696","citation_count":42,"is_preprint":false},{"pmid":"33851776","id":"PMC_33851776","title":"Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation.","date":"2021","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33851776","citation_count":42,"is_preprint":false},{"pmid":"36608670","id":"PMC_36608670","title":"A central role for regulated protein stability in the control of TFE3 and MITF by nutrients.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/36608670","citation_count":41,"is_preprint":false},{"pmid":"35180736","id":"PMC_35180736","title":"Chameleon TFE3-translocation RCC and How Gene Partners Can Change Morphology: Accurate Diagnosis Using Contemporary Modalities.","date":"2022","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35180736","citation_count":39,"is_preprint":false},{"pmid":"29272888","id":"PMC_29272888","title":"Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas.","date":"2017","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29272888","citation_count":39,"is_preprint":false},{"pmid":"30908700","id":"PMC_30908700","title":"RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.","date":"2019","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/30908700","citation_count":36,"is_preprint":false},{"pmid":"17279346","id":"PMC_17279346","title":"SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17279346","citation_count":35,"is_preprint":false},{"pmid":"31408245","id":"PMC_31408245","title":"A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.","date":"2019","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31408245","citation_count":35,"is_preprint":false},{"pmid":"33019842","id":"PMC_33019842","title":"PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33019842","citation_count":34,"is_preprint":false},{"pmid":"26840265","id":"PMC_26840265","title":"Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26840265","citation_count":33,"is_preprint":false},{"pmid":"33514585","id":"PMC_33514585","title":"Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.","date":"2021","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33514585","citation_count":33,"is_preprint":false},{"pmid":"37216554","id":"PMC_37216554","title":"The KEAP1-NRF2 pathway regulates TFEB/TFE3-dependent lysosomal biogenesis.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37216554","citation_count":32,"is_preprint":false},{"pmid":"35980471","id":"PMC_35980471","title":"TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.","date":"2022","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35980471","citation_count":32,"is_preprint":false},{"pmid":"36719671","id":"PMC_36719671","title":"Phosphorylation of EIF2S1 (eukaryotic translation initiation factor 2 subunit alpha) is indispensable for nuclear translocation of TFEB and TFE3 during ER stress.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36719671","citation_count":31,"is_preprint":false},{"pmid":"38225393","id":"PMC_38225393","title":"Corynoxine promotes TFEB/TFE3-mediated autophagy and alleviates Aβ pathology in Alzheimer's disease models.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38225393","citation_count":30,"is_preprint":false},{"pmid":"12902986","id":"PMC_12902986","title":"PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12902986","citation_count":30,"is_preprint":false},{"pmid":"33637706","id":"PMC_33637706","title":"Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33637706","citation_count":30,"is_preprint":false},{"pmid":"27910947","id":"PMC_27910947","title":"Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation.","date":"2016","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/27910947","citation_count":28,"is_preprint":false},{"pmid":"35848761","id":"PMC_35848761","title":"PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-related Mesenchymal Neoplasia.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35848761","citation_count":28,"is_preprint":false},{"pmid":"37029109","id":"PMC_37029109","title":"ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37029109","citation_count":27,"is_preprint":false},{"pmid":"27673450","id":"PMC_27673450","title":"ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.","date":"2016","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27673450","citation_count":27,"is_preprint":false},{"pmid":"35313207","id":"PMC_35313207","title":"The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35313207","citation_count":25,"is_preprint":false},{"pmid":"36935008","id":"PMC_36935008","title":"TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36935008","citation_count":24,"is_preprint":false},{"pmid":"34769510","id":"PMC_34769510","title":"Translation Inhibitors Activate Autophagy Master Regulators TFEB and TFE3.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34769510","citation_count":24,"is_preprint":false},{"pmid":"37499055","id":"PMC_37499055","title":"Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.","date":"2023","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37499055","citation_count":24,"is_preprint":false},{"pmid":"35230915","id":"PMC_35230915","title":"The FACT complex facilitates expression of lysosomal and antioxidant genes through binding to TFEB and TFE3.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35230915","citation_count":23,"is_preprint":false},{"pmid":"32830550","id":"PMC_32830550","title":"Transcription factor EB and TFE3: new metabolic coordinators mediating adaptive responses to exercise in skeletal muscle?","date":"2020","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32830550","citation_count":23,"is_preprint":false},{"pmid":"38168055","id":"PMC_38168055","title":"TMEM55B links autophagy flux, lysosomal repair, and TFE3 activation in response to oxidative stress.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38168055","citation_count":22,"is_preprint":false},{"pmid":"36732771","id":"PMC_36732771","title":"TNEA therapy promotes the autophagic degradation of NLRP3 inflammasome in a transgenic mouse model of Alzheimer's disease via TFEB/TFE3 activation.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36732771","citation_count":22,"is_preprint":false},{"pmid":"35316161","id":"PMC_35316161","title":"TFEB- and TFE3-dependent autophagy activation supports cancer proliferation in the absence of centrosomes.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35316161","citation_count":22,"is_preprint":false},{"pmid":"32576448","id":"PMC_32576448","title":"TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract.","date":"2020","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32576448","citation_count":20,"is_preprint":false},{"pmid":"36906611","id":"PMC_36906611","title":"Emerging roles of TFE3 in metabolic regulation.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36906611","citation_count":19,"is_preprint":false},{"pmid":"31272105","id":"PMC_31272105","title":"Loss of FLCN inhibits canonical WNT signaling via TFE3.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31272105","citation_count":19,"is_preprint":false},{"pmid":"31341686","id":"PMC_31341686","title":"Hepatic YAP1-TFE3 Rearranged Epithelioid Hemangioendothelioma.","date":"2019","source":"Case reports in gastrointestinal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31341686","citation_count":17,"is_preprint":false},{"pmid":"39915638","id":"PMC_39915638","title":"Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39915638","citation_count":16,"is_preprint":false},{"pmid":"39169706","id":"PMC_39169706","title":"TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape.","date":"2024","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/39169706","citation_count":16,"is_preprint":false},{"pmid":"35786165","id":"PMC_35786165","title":"Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35786165","citation_count":16,"is_preprint":false},{"pmid":"38926757","id":"PMC_38926757","title":"Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38926757","citation_count":15,"is_preprint":false},{"pmid":"32676967","id":"PMC_32676967","title":"Ocular PEComas are frequently melanotic and TFE3-translocated: report of two cases including the first description of PRCC-TFE3 fusion in PEComa.","date":"2020","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32676967","citation_count":15,"is_preprint":false},{"pmid":"39486419","id":"PMC_39486419","title":"mTORC1 restricts TFE3 activity by auto-regulating its presence on lysosomes.","date":"2024","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/39486419","citation_count":14,"is_preprint":false},{"pmid":"39410016","id":"PMC_39410016","title":"TFE3-Rearranged Tumors of the Kidney: An Emerging Conundrum.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39410016","citation_count":14,"is_preprint":false},{"pmid":"40381702","id":"PMC_40381702","title":"Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry.","date":"2025","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40381702","citation_count":14,"is_preprint":false},{"pmid":"30269476","id":"PMC_30269476","title":"TFE3-Expressing Perivascular Epithelioid Cell Tumor of the Breast.","date":"2018","source":"Journal of pathology and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30269476","citation_count":14,"is_preprint":false},{"pmid":"26872381","id":"PMC_26872381","title":"Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26872381","citation_count":13,"is_preprint":false},{"pmid":"33145941","id":"PMC_33145941","title":"TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33145941","citation_count":13,"is_preprint":false},{"pmid":"39349971","id":"PMC_39349971","title":"Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/39349971","citation_count":12,"is_preprint":false},{"pmid":"35912477","id":"PMC_35912477","title":"TFE3 Rearrangement and Expression in Renal Cell Carcinoma.","date":"2022","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35912477","citation_count":12,"is_preprint":false},{"pmid":"38380774","id":"PMC_38380774","title":"Epithelioid hemangioendothelioma (EHE) with WWTR1::TFE3 gene fusion, a novel fusion variant.","date":"2024","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38380774","citation_count":12,"is_preprint":false},{"pmid":"39593216","id":"PMC_39593216","title":"TFE3 -rearranged Head and Neck Neoplasms : Twenty-two Cases Spanning the Morphologic Continuum Between Alveolar Soft Part Sarcoma and PEComa and Highlighting Genotypic Diversity.","date":"2024","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39593216","citation_count":12,"is_preprint":false},{"pmid":"38971946","id":"PMC_38971946","title":"Renal epithelioid angiomyolipomas overexpress TFE3 and the TFE3-regulated gene TRIM63 in the absence of TFE3 rearrangement.","date":"2024","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38971946","citation_count":12,"is_preprint":false},{"pmid":"36785787","id":"PMC_36785787","title":"Beta-coronaviruses exploit cellular stress responses by modulating TFEB and TFE3 activity.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36785787","citation_count":12,"is_preprint":false},{"pmid":"38104891","id":"PMC_38104891","title":"Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38104891","citation_count":12,"is_preprint":false},{"pmid":"39085357","id":"PMC_39085357","title":"Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39085357","citation_count":11,"is_preprint":false},{"pmid":"34345304","id":"PMC_34345304","title":"NRF-1 directly regulates TFE3 and promotes the proliferation of renal cancer cells.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34345304","citation_count":11,"is_preprint":false},{"pmid":"34874592","id":"PMC_34874592","title":"A YAP1::TFE3 cutaneous low-grade fibromyxoid neoplasm: A novel entity!","date":"2021","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34874592","citation_count":11,"is_preprint":false},{"pmid":"40195022","id":"PMC_40195022","title":"TFEB and TFE3 regulate STING1-dependent immune responses by controlling type I interferon signaling.","date":"2025","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/40195022","citation_count":10,"is_preprint":false},{"pmid":"36669395","id":"PMC_36669395","title":"TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/36669395","citation_count":10,"is_preprint":false},{"pmid":"37468653","id":"PMC_37468653","title":"Novel NONO::TFE3 fusion and ALK co-expression identified in a subset of cutaneous microcystic/reticular schwannoma.","date":"2023","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37468653","citation_count":10,"is_preprint":false},{"pmid":"31833172","id":"PMC_31833172","title":"TFE3-associated neurodevelopmental disorder: A distinct recognizable syndrome.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31833172","citation_count":10,"is_preprint":false},{"pmid":"23760492","id":"PMC_23760492","title":"Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).","date":"2013","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23760492","citation_count":10,"is_preprint":false},{"pmid":"32339358","id":"PMC_32339358","title":"PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.","date":"2020","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/32339358","citation_count":10,"is_preprint":false},{"pmid":"38657118","id":"PMC_38657118","title":"ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38657118","citation_count":10,"is_preprint":false},{"pmid":"34912803","id":"PMC_34912803","title":"TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson's Disease.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34912803","citation_count":10,"is_preprint":false},{"pmid":"38266162","id":"PMC_38266162","title":"TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38266162","citation_count":9,"is_preprint":false},{"pmid":"40239600","id":"PMC_40239600","title":"SFPQ::TFE3-rearranged PEComa: Differences and analogies with renal cell carcinoma carrying the same translocation.","date":"2025","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/40239600","citation_count":9,"is_preprint":false},{"pmid":"38267572","id":"PMC_38267572","title":"TFEB and TFE3 cooperate in regulating inorganic arsenic-induced autophagy-lysosome impairment and immuno-dysfunction in primary dendritic cells.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38267572","citation_count":9,"is_preprint":false},{"pmid":"31043173","id":"PMC_31043173","title":"Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis.","date":"2019","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31043173","citation_count":9,"is_preprint":false},{"pmid":"37770905","id":"PMC_37770905","title":"LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD+ kinase-independent manner.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37770905","citation_count":9,"is_preprint":false},{"pmid":"38326311","id":"PMC_38326311","title":"ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38326311","citation_count":8,"is_preprint":false},{"pmid":"40138313","id":"PMC_40138313","title":"Antagonistic roles for MITF and TFE3 in melanoma plasticity.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40138313","citation_count":8,"is_preprint":false},{"pmid":"40059270","id":"PMC_40059270","title":"Isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis.","date":"2025","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40059270","citation_count":8,"is_preprint":false},{"pmid":"28713889","id":"PMC_28713889","title":"TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28713889","citation_count":8,"is_preprint":false},{"pmid":"38643162","id":"PMC_38643162","title":"Dimorphic effect of TFE3 in determining mitochondrial and lysosomal content in muscle following denervation.","date":"2024","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/38643162","citation_count":8,"is_preprint":false},{"pmid":"34291749","id":"PMC_34291749","title":"Orbital TFE3-Rearranged Perivascular Epithelioid Cell Tumor: A Case Report and Review of the Literature.","date":"2021","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34291749","citation_count":8,"is_preprint":false},{"pmid":"29901594","id":"PMC_29901594","title":"Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29901594","citation_count":8,"is_preprint":false},{"pmid":"33845743","id":"PMC_33845743","title":"NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.","date":"2021","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/33845743","citation_count":8,"is_preprint":false},{"pmid":"37269887","id":"PMC_37269887","title":"Neratinib is a TFEB and TFE3 activator that potentiates autophagy and unbalances energy metabolism in ERBB2+ breast cancer cells.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37269887","citation_count":7,"is_preprint":false},{"pmid":"38588851","id":"PMC_38588851","title":"TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment.","date":"2024","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38588851","citation_count":7,"is_preprint":false},{"pmid":"36827899","id":"PMC_36827899","title":"TFE3-mediated impairment of lysosomal biogenesis and defective autophagy contribute to fluoride-induced hepatotoxicity.","date":"2023","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/36827899","citation_count":7,"is_preprint":false},{"pmid":"31774608","id":"PMC_31774608","title":"A renal cell carcinoma with EWSR1-TFE3 fusion gene.","date":"2019","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31774608","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56518,"output_tokens":9256,"usd":0.154197,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19247,"output_tokens":6138,"usd":0.124842,"stage2_stop_reason":"end_turn"},"total_usd":0.279039,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"TFE3 nuclear translocation in response to ER stress requires PERK kinase and calcineurin phosphatase, but is independent of mTORC1. Once nuclear, TFE3 directly transcriptionally upregulates ATF4 and other UPR genes to enhance cellular stress response.\",\n      \"method\": \"Chemical ER stressor treatment, PERK/calcineurin inhibition, nuclear translocation assays, transcriptional reporter assays in mammalian cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (pharmacological inhibition of PERK and calcineurin, nuclear localization assays, transcriptional activation assays), single lab but rigorous mechanistic dissection\",\n      \"pmids\": [\"26813791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AMPK directly phosphorylates TFE3 on three serine residues (analogous to S466/467/469 in TFEB), which is required for TFE3 transcriptional activity upon nutrient starvation or FLCN depletion. mTORC1 controls TFE3 cytosolic retention, whereas AMPK is specifically required for TFE3 transcriptional activity — a dual and opposing regulatory mechanism.\",\n      \"method\": \"In vitro phosphorylation assays (GST pulldown with AMPK), site-directed mutagenesis (serine-to-alanine mutations), AMPK knockout/pharmacological inhibition, reporter assays in MEFs and cancer cell lines\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, multiple genetic and pharmacological validations, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"33734022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4/6 interact with and phosphorylate TFE3 (and TFEB) in the nucleus, promoting their nuclear export and cytoplasmic retention, thereby inactivating lysosome biogenesis programs. During the cell cycle, lysosome numbers increase in S and G2/M phases when cyclin D turnover diminishes CDK4/6 activity.\",\n      \"method\": \"Co-immunoprecipitation, CDK4/6 chemical and genetic inactivation, nuclear/cytoplasmic fractionation, cell-cycle-stage lysosome quantification in mammalian cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP showing CDK4/6-TFE3 interaction, chemical and genetic perturbation with defined subcellular and functional readouts, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"32662822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Amino acids promote recruitment of TFE3 to the lysosomal surface via Rag GTPases, activating an evolutionarily conserved phospho-degron that leads to ubiquitination by CUL1β-TrCP and proteasomal degradation of TFE3. A conserved alpha-helix in TFE3 is required for interaction with RagA. TFE3 missense mutations within the RagA-TFE3 interface cause a severe neurodevelopmental syndrome. The phospho-degron is recurrently lost in oncogenic TFE3 genomic translocations.\",\n      \"method\": \"Lysosomal fractionation, ubiquitination assays, co-immunoprecipitation with Rag GTPases, mutagenesis of degron and RagA-binding helix, proteasome inhibitor experiments in mammalian cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution-level biochemistry (lysosomal recruitment, ubiquitination, degron mapping), mutagenesis, and disease-variant validation in a single rigorous study\",\n      \"pmids\": [\"36608670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TFE3 (and TFEB) directly bind to multiple cognate E-box sites in the Cd40lg promoter and are required for maximal CD40 ligand expression in activated CD4+ T cells. Combined T-cell-specific inactivation of TFE3 and TFEB results in hyper-IgM syndrome due to impaired CD40L expression, demonstrating that TFE3 and TFEB are physiologically redundant activators of Cd40lg.\",\n      \"method\": \"T-cell-specific conditional double knockout mice, EMSA/promoter binding assays, promoter-reporter assays, immunological phenotyping\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function (double KO mice), direct promoter binding demonstrated, clear immunological phenotype, rigorous in vivo and in vitro validation\",\n      \"pmids\": [\"16936731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFEB and TFE3 display circadian nuclear activation over the 24-h cycle and directly regulate expression of Rev-erbα (Nr1d1), a core clock repressor. Genetic ablation of TFEB and TFE3 in mice deregulates circadian autophagy gene oscillation and alters circadian wheel-running behavior. ChIP-seq cistrome analysis showed extensive overlap between TFEB/TFE3 and REV-ERBα binding sites at autophagy and metabolic genes.\",\n      \"method\": \"TFEB/TFE3 double knockout mice, ChIP-seq, RNA-seq, circadian behavioral assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mice with behavioral phenotype, ChIP-seq for direct target identification, replicated with multiple methods in vivo and in vitro\",\n      \"pmids\": [\"31126958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The PSF-TFE3 fusion oncoprotein (arising from SFPQ-TFE3 translocation) localizes to the endosomal compartment rather than the nucleus, unlike wild-type TFE3 or PSF. PSF-TFE3 sequesters wild-type TFE3 and p53 in the extranuclear compartment, rendering them functionally null. siRNA knockdown of PSF-TFE3 in renal carcinoma cells (UOK-145) redistributes endogenous TFE3 and p53 back to the nucleus.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence, siRNA knockdown in endogenous tRCC cell line (UOK-145), co-localization studies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments plus siRNA rescue in endogenous cell line, single lab, multiple methods but no structural confirmation\",\n      \"pmids\": [\"12902986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TFE3 strongly activates IRS-2 expression in the liver and regulates hepatic insulin signaling. TFE3 acts in synergy with Foxo1 at the IRS-2 promoter to promote insulin sensitivity, antagonizing SREBP-1c which suppresses IRS-2. TFE3 and SREBP-1c reciprocally regulate IRS-2 expression and insulin sensitivity.\",\n      \"method\": \"Promoter reporter assays, transcriptional activation experiments in hepatic cell models, genetic and biochemical interaction studies (review citing primary experimental work)\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — review paper summarizing primary experimental work on IRS-2 regulation; mechanistic details referenced from original studies but confidence limited by review format\",\n      \"pmids\": [\"17279346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of FLCN leads to increased nuclear TFE3, which suppresses canonical WNT signaling. Silencing TFE3 in FLCN-deficient cells completely reversed the decreased WNT pathway activity phenotype, placing TFE3 downstream of FLCN and upstream of WNT in lung fibroblasts.\",\n      \"method\": \"Flcn knockout in MEFs and human fetal lung fibroblasts (MRC-5), RNA-seq, TCF/LEF reporter assays, TFE3 siRNA rescue experiments\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (FLCN KO + TFE3 silencing rescue), TCF/LEF reporter readout, single lab\",\n      \"pmids\": [\"31272105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VPS41 loss of function causes cytosolic redistribution of mTORC1, leading to constitutive nuclear localization of TFE3 and enhanced LC3-II levels, but with a reduced autophagic response to nutrient starvation, demonstrating that HOPS complex-mediated lysosomal function is required for proper mTORC1-dependent TFE3 regulation.\",\n      \"method\": \"Patient fibroblasts with compound heterozygous VPS41 mutations, VPS41 siRNA in HeLa cells, subcellular fractionation, mTORC1 substrate phosphorylation assays\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived fibroblasts and siRNA knockdown with nuclear localization and mTORC1 substrate readouts, single study\",\n      \"pmids\": [\"33851776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TFEB and TFE3 interact with the FACT histone chaperone complex (SSRP1/SUPT16H). This interaction is induced by nuclear translocation of TFEB/TFE3 upon nutrient deprivation or oxidative stress. FACT depletion or inhibition (curaxin) severely impairs induction of antioxidant and lysosomal gene targets without affecting TFEB activation, stability, or promoter binding, demonstrating that FACT chromatin remodeling is required for efficient TFE3 transcriptional output.\",\n      \"method\": \"Co-immunoprecipitation of TFEB/TFE3 with SSRP1/SUPT16H, siRNA depletion of FACT components, curaxin pharmacological inhibition, ChIP assays, gene expression profiling\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, siRNA depletion, and pharmacological inhibition with defined transcriptional readouts; single lab\",\n      \"pmids\": [\"35230915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM28 promotes ubiquitination and proteasome-mediated degradation of TFE3, restraining TFE3-dependent autophagic gene expression in kidney cancer cells. TFE3 interacts with and recruits the histone H3K27 demethylase KDM6A to autophagic gene promoters; KDM6A increases H3K4me3 (rather than demethylating H3K27) at TFE3 target genes to upregulate their expression.\",\n      \"method\": \"Co-immunoprecipitation (TFE3-KDM6A), ubiquitination assays, TRIM28 knockdown/overexpression, histone modification ChIP, proliferation assays in kidney cancer cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, ChIP for histone marks, genetic perturbation; single lab with multiple methods\",\n      \"pmids\": [\"36935008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Both TFEB and TFE3 are substrates of PLK4 (polo-like kinase 4). Centrosome depletion inactivates PLK4, resulting in TFEB/TFE3 dephosphorylation and nuclear translocation with transcriptional activation of autophagy and lysosome genes, supporting acentrosomal cancer cell proliferation.\",\n      \"method\": \"PLK4 knockout/inhibition, biochemical phosphorylation assays, nuclear translocation imaging, genetic epistasis with TFEB/TFE3 double KO in cancer cells\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical substrate identification, genetic epistasis with double KO, single lab\",\n      \"pmids\": [\"35316161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EIF2S1 (eIF2α) phosphorylation is required for nuclear translocation of TFE3 during ER stress. PPP3/calcineurin-mediated dephosphorylation and YWHA/14-3-3 dissociation are required but insufficient for nuclear retention of TFE3 during ER stress; EIF2AK3/PERK is upstream of this pathway. Overexpression of active ATF6 or XBP1s/ATF4 differentially rescues TFE3 nuclear translocation defects in eIF2α phosphorylation-deficient cells.\",\n      \"method\": \"EIF2S1 phosphorylation-deficient (S51A) cells, nuclear translocation assays, calcineurin and 14-3-3 dissociation experiments, adenoviral overexpression of UPR effectors, autophagy flux assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (knock-in phospho-deficient cells) plus pharmacological dissection, multiple UPR branch rescue experiments, single lab\",\n      \"pmids\": [\"36719671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"mTORC1 restricts TFE3 activity through an auto-regulatory negative feedback: activated mTOR mutants display low lysosome occupancy due to release of mTORC1 from lysosomes dependent on its own kinase activity, causing hypo-phosphorylation and nuclear accumulation of TFE3. Rheb-activated mTORC1 does not increase cytoplasmic/lysosomal mTORC1 ratio, indicating the existence of distinct mTORC1 pools with different substrate specificity toward TFE3.\",\n      \"method\": \"Activated mTOR mutant cell lines, lysosomal fractionation, TFE3 nuclear localization assays, Rheb overexpression experiments in human cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lysosomal fractionation and nuclear localization with activated kinase mutants, single lab\",\n      \"pmids\": [\"39486419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TMEM55B sequesters the FLCN/FNIP complex at lysosomes in response to oxidative stress, thereby facilitating TFE3 nuclear translocation and transcriptional activation of stress-response genes. tmem55 knockout zebrafish show increased susceptibility to oxidative stress, confirming in vivo relevance.\",\n      \"method\": \"Co-immunoprecipitation (TMEM55B-FLCN/FNIP), TFE3 nuclear translocation assays, TMEM55B knockout zebrafish model, arsenite stress experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, nuclear translocation assays, in vivo zebrafish KO; multiple methods but primarily single lab\",\n      \"pmids\": [\"38168055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The ASPL-TFE3 (ASPSCR1-TFE3) fusion oncoprotein directly activates transcription of p21 (CDKN1A) in a p53-independent manner through binding to the p21 promoter region, causing cell cycle arrest and cellular senescence in mesenchymal stem cells.\",\n      \"method\": \"Ectopic expression of ASPL-TFE3 in 293 cells and tetracycline-inducible mesenchymal stem cells, p21 promoter luciferase reporter, RT-PCR, senescence-associated β-galactosidase assay, p21 siRNA epistasis\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay plus siRNA epistasis confirming p21-dependent senescence, single lab\",\n      \"pmids\": [\"27673450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TAZ-CAMTA1 and YAP-TFE3 fusion oncoproteins both interact with YEATS2 and ZZZ3 (components of the ATAC histone acetyltransferase complex) despite dissimilarity of their C-terminal fusion partners. This interaction drives a unique transcriptome by hyperactivating TEAD-based transcription and modulating chromatin via the ATAC complex.\",\n      \"method\": \"Combined proteomic/genetic screen (Co-IP/MS), integrative ChIP-seq and RNA-seq in human and murine cell lines expressing fusion proteins\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-confirmed Co-IP interaction, integrated ChIP-seq/RNA-seq, single study but multiple orthogonal methods\",\n      \"pmids\": [\"33913810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRCC-TFE3 fusion protein, constitutively localized in the nucleus, transcriptionally activates the E3 ubiquitin ligase PRKN/parkin, driving PINK1-PRKN-dependent mitophagy that promotes tRCC cell survival under mitochondrial oxidative damage and cell proliferation by decreasing mitochondrial ROS. PRCC-TFE3 also activates PPARGC1A/PGC1α-NRF1 to accelerate mitochondrial biogenesis.\",\n      \"method\": \"Nuclear localization studies of PRCC-TFE3, ChIP/reporter assays for PRKN promoter, mitophagy flux assays, ROS measurement, proliferation assays in PRCC-TFE3 tRCC cell lines\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter activation, mitophagy flux assays, and ROS measurements in fusion-expressing cells; single lab\",\n      \"pmids\": [\"33019842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRCC-TFE3 fusion positively regulates expression of dynamin-related protein 1 (Drp1) and fission protein 1 (Fis1), altering mitochondrial distribution and promoting cell migration and invasion independently of MMP-2/MMP-9 in tRCC cells.\",\n      \"method\": \"PRCC-TFE3 expression in tRCC cell lines, Drp1/Fis1 Western blot and RT-PCR, mitochondrial distribution imaging, migration/invasion assays\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single set of methods without mechanistic dissection of how PRCC-TFE3 regulates Drp1\",\n      \"pmids\": [\"32339358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFE3 chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) in a SFPQ-TFE3 tRCC patient-derived xenograft showed strong enrichment for PI3K/AKT/mTOR pathway genes as direct transcriptional targets. TFE3 knockdown decreased IRS-1 expression, linking TFE3 to IRS-1/PI3K/mTOR signaling in translocation RCC.\",\n      \"method\": \"TFE3 ChIP-seq in PDX model, TFE3 siRNA knockdown, phospho-S6 and phospho-4EBP1 Western blot\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq for direct target identification plus siRNA knockdown with pathway readout; single lab, patient-derived xenograft model\",\n      \"pmids\": [\"30061365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TFEB and TFE3 translocate to the nucleus in response to beta-coronavirus infection via a calcineurin-dependent mechanism, and bind to promoters of multiple lysosomal and immune genes. TFE3/TFEB depletion significantly decreases MHV-induced upregulation of immune regulators, and overexpression of either factor increases cytokine/chemokine expression. TFEB/TFE3 also modulate type I IFN signaling by controlling IRF3 activation.\",\n      \"method\": \"Beta-coronavirus infection of macrophages, TFEB/TFE3 nuclear translocation assays, calcineurin inhibition, TFEB/TFE3 siRNA depletion, promoter ChIP, gene expression analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for promoter binding, siRNA depletion with gene expression readout, calcineurin pharmacological dissection; single lab\",\n      \"pmids\": [\"36785787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NUPR1 maintains autophagic flux and lysosomal function by directly increasing TFE3 transcriptional activity. NUPR1 knockdown in OSCC cells reduces TFE3 activity, impairing autophagy and decreasing cancer cell proliferation and metastasis in vitro and in vivo.\",\n      \"method\": \"Quantitative proteomics (TMT-based), NUPR1 stable knockdown, TFE3 activity reporter assays, in vitro and in vivo proliferation/metastasis assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — NUPR1-TFE3 axis defined by proteomic screen and knockdown with activity readout, but direct molecular mechanism of NUPR1-TFE3 interaction not fully established\",\n      \"pmids\": [\"35462576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASPSCR1::TFE3 interacts with VCP/p97 (AAA+ ATPase), which co-distributes with the fusion protein across chromatin at enhancers genome-wide. VCP hexameric assembly and enzymatic activity are required for the oncogenic transcriptional signature of ASPSCR1::TFE3, and both proteins are co-dependent for cancer cell proliferation and tumorigenesis in vitro and in mouse models of ASPS and RCC.\",\n      \"method\": \"Co-immunoprecipitation/MS (nuclear complex proteomics), ChIP-seq for ASPSCR1::TFE3 and VCP co-occupancy, HiChIP chromatin conformation, VCP ATPase mutants, in vivo mouse tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — MS-confirmed Co-IP, ChIP-seq co-occupancy, HiChIP chromatin conformation, enzymatic mutants, and in vivo epistasis; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"38326311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ASPSCR1::TFE3 drives ASPS by regulating transcriptional programs controlling angiogenesis through super-enhancer (SE) modulation. Loss of ASPSCR1::TFE3 expression induces SE redistribution at angiogenesis genes. Epigenomic CRISPR/dCas9 screening identifies Pdgfb, Rab27a, Sytl2, and Vwf as critical angiogenesis targets of ASPSCR1::TFE3 via SE activity. ASPSCR1::TFE3 is dispensable for in vitro tumor maintenance but required for in vivo tumor development via angiogenesis.\",\n      \"method\": \"ASPSCR1::TFE3 inducible expression/depletion, H3K27ac ChIP-seq for SE mapping, CRISPR/dCas9 epigenomic screen, in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq SE mapping, CRISPR functional screen, and in vivo validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"37029109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASPSCR1::TFE3 directly interacts with key epigenetic regulators at enhancers and promoters. Among effector programs, it drives cyclin D1 expression to support cell proliferation. Disruption of cyclin D1/CDK4 signaling impairs ASPS proliferative capacity.\",\n      \"method\": \"ChIP-seq, transcriptome profiling of ASPS tumors and preclinical models, CDK4/6 inhibitor treatment, CDK4/6 + anti-angiogenesis combination in xenografts\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq interaction at enhancers, pharmacological epistasis, in vivo xenograft validation; single lab\",\n      \"pmids\": [\"38657118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NONO-TFE3 fusion protein directly transcriptionally activates HIF1A expression (confirmed by ChIP and luciferase reporter assay), promoting aerobic glycolysis and angiogenesis under hypoxia in NONO-TFE3 tRCC.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, RT-qPCR, glycolysis/lactate measurements, tube formation and migration assays in UOK109 cells (NONO-TFE3 tRCC)\",\n      \"journal\": \"Current cancer drug targets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP + reporter assay for direct target activation, functional metabolic readouts; single lab\",\n      \"pmids\": [\"33845743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFE3 splicing-factor (TFE3-SF) fusion proteins (e.g., SFPQ-TFE3, NONO-TFE3) drive oncogenic transformation through both transcriptional and RNA splicing activities, differentially altering the transcriptome and splicing landscape in a fusion-partner-dependent manner. Inhibiting TFE3-SF dimerization reverses oncogenic activity.\",\n      \"method\": \"In silico structure prediction, transcriptome and splicing profiling, FRET-based dimerization assay, HTHCS of FDA-approved drug library, 2D/3D PDX validation models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET dimerization assay, transcriptome/splicing profiling, PDX validation; multiple methods but partially computational\",\n      \"pmids\": [\"38266162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFE3 gene fusions transcriptionally rewire translocation RCC toward oxidative phosphorylation (OXPHOS), creating dependence on NADH reductive stress management. Genome-scale CRISPR screening identified EGLN1 (PHD2) as a TFE3 fusion-selective vulnerability; EGLN1 inhibition stabilizes HIF-1α and reprograms metabolism away from OXPHOS, suppressing tRCC growth.\",\n      \"method\": \"Genome-scale CRISPR screen, transcriptome profiling, metabolic flux assays (OXPHOS measurement), EGLN1 genetic/pharmacological inhibition in tRCC cell lines and in vivo models\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-scale CRISPR screen, metabolic profiling, and in vivo validation; multiple orthogonal methods establishing TFE3-driven OXPHOS mechanism\",\n      \"pmids\": [\"39915638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFE3 drives the mesenchymal/invasive phenotype in melanoma. MITF directly or indirectly activates expression of FNIP1, FNIP2, and FLCN (non-canonical mTORC1 pathway components), which promote cytoplasmic retention and lysosome-mediated degradation of TFE3, thereby suppressing the mesenchymal state. Deletion of TFE3 in MITF-low melanoma cells suppresses migration and metastasis.\",\n      \"method\": \"TFE3 deletion in MITF-low melanoma cell lines, FLCN/FNIP1/FNIP2 overexpression, subcellular fractionation, in vitro migration and in vivo metastasis assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion with migratory/metastatic phenotype, pathway epistasis via FLCN/FNIP expression; single lab\",\n      \"pmids\": [\"40138313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FLCN acts as a negative regulator of TFE3 (and TFEB) by enabling their phosphorylation by mTORC1. Both Tfeb and Tfe3 contribute in a differential and cooperative manner to kidney cystogenesis in Flcn KO mice. Silencing either TFE3 or TFEB rescues tumorigenesis in human BHD renal tumor cell line-derived xenografts.\",\n      \"method\": \"Flcn/Tfeb/Tfe3 double and triple KO mice, BHD patient-derived tumor analysis, xenograft rescue experiments with TFE3/TFEB silencing\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — triple KO genetic epistasis in mice, patient-derived tumor analysis, and xenograft rescue; multiple in vivo models\",\n      \"pmids\": [\"36987696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"WWTR1::TFE3 fusion protein promotes colony formation in soft agar (oncogenic transformation). The TEAD-binding domain of WWTR1 in the fusion is required for this transformative effect, as mutation of the WWTR1 domain to inhibit TEAD binding abrogates WWTR1::TFE3-driven transformation.\",\n      \"method\": \"Soft agar colony formation assay in NIH3T3 cells, TEAD-binding domain mutagenesis, targeted RNA-seq for fusion identification\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro transformation assay with mutagenesis of functional domain; single case report with in vitro mechanistic follow-up\",\n      \"pmids\": [\"38380774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRF-1 (Nuclear Respiratory Factor 1) directly binds to the promoter region of TFE3 and transcriptionally activates TFE3 expression. NRF-1 knockdown reduces TFE3 levels, inhibits mTOR pathway activation (phospho-AKT, phospho-S6), blocks cell cycle progression, and reduces mitochondrial biogenesis; TFE3 overexpression rescues these effects.\",\n      \"method\": \"Luciferase promoter reporter assay, ChIP of NRF-1 at TFE3 promoter, shRNA knockdown, TFE3 rescue overexpression, flow cytometry cell cycle analysis in 786-O and 293T cells\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP + promoter reporter for direct transcriptional regulation, genetic rescue; single lab\",\n      \"pmids\": [\"34345304\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFE3 is a bHLH-LZ transcription factor whose activity is primarily controlled by subcellular localization: under nutrient-replete conditions, Rag GTPases recruit TFE3 to the lysosomal surface where mTORC1 phosphorylates it, promoting cytoplasmic retention via 14-3-3 binding and also targeting it for CUL1β-TrCP-mediated ubiquitination and proteasomal degradation via a conserved phospho-degron; upon starvation, AMPK phosphorylates TFE3 on distinct serine residues to license transcriptional activity, while calcineurin-mediated dephosphorylation and 14-3-3 dissociation enable nuclear translocation; in the nucleus, TFE3 activates the CLEAR gene network (lysosomal biogenesis, autophagy) and additional programs including ATF4/UPR genes, IRS-2 (hepatic insulin signaling), CD40L (T-cell immunity), Rev-erbα (circadian clock), and HIF1A/PRKN (in fusion contexts), often requiring cofactors such as the FACT histone chaperone complex; oncogenic chromosomal translocations (e.g., ASPSCR1::TFE3, PRCC-TFE3, SFPQ-TFE3, NONO-TFE3) constitutively localize TFE3 to the nucleus by bypassing mTORC1/Rag-dependent regulation, driving transcriptional rewiring toward OXPHOS, angiogenesis, and other tumor-promoting programs, with ASPSCR1::TFE3 additionally recruiting VCP/p97 as an obligate co-factor to organize enhancer loops.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TFE3 is a basic helix-loop-helix transcription factor that couples nutrient, stress, and cell-cycle signals to the activation of lysosomal, autophagic, and metabolic gene programs through tightly regulated nucleocytoplasmic shuttling [#3, #14]. Under nutrient-replete conditions, amino acids drive Rag-GTPase-dependent recruitment of TFE3 to the lysosomal surface via a conserved alpha-helix that contacts RagA, where an evolutionarily conserved phospho-degron triggers CUL1\\u03b2-TrCP-mediated ubiquitination and proteasomal degradation; missense mutations at the RagA-TFE3 interface cause a severe neurodevelopmental syndrome, and this phospho-degron is recurrently lost in oncogenic TFE3 translocations [#3]. mTORC1 enforces cytoplasmic retention, with an autoregulatory feedback in which active mTOR releases from lysosomes to permit TFE3 nuclear accumulation [#14], while FLCN promotes mTORC1-dependent phosphorylation as a negative regulator [#30]. Diverse signals license nuclear entry: AMPK directly phosphorylates three serines required for transcriptional activity upon starvation [#1]; PERK/eIF2\\u03b1 signaling and calcineurin-mediated dephosphorylation with 14-3-3 dissociation drive translocation during ER and oxidative stress, including TMEM55B-dependent sequestration of FLCN/FNIP at lysosomes [#0, #13, #15]; and CDK4/6 and PLK4 phosphorylation restrain nuclear activity to gate lysosome biogenesis with the cell cycle and centrosome status [#2, #12]. In the nucleus, TFE3 requires the FACT histone chaperone complex (SSRP1/SUPT16H) and recruits the H3K27 demethylase KDM6A for efficient transcriptional output, and is destabilized by TRIM28-mediated ubiquitination [#10, #11]. Beyond the CLEAR/autophagy network, TFE3 activates ATF4/UPR genes [#0], IRS-2 in hepatic insulin signaling in synergy with Foxo1 [#7], Cd40lg in CD4+ T cells (redundantly with TFEB, with double loss causing hyper-IgM syndrome) [#4], Rev-erb\\u03b1 in the circadian clock [#5], and immune/interferon genes during coronavirus infection [#21]. Oncogenic chromosomal translocations fuse TFE3 to partners such as ASPSCR1, PRCC, SFPQ, NONO, and WWTR1, bypassing mTORC1/Rag regulation to constitutively localize the fusion to the nucleus and rewire transcription toward OXPHOS, angiogenesis, and mitochondrial programs; ASPSCR1::TFE3 obligately recruits the AAA+ ATPase VCP/p97 to organize enhancer loops driving its oncogenic signature [#23, #24, #28].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that TFE3 has a physiological role beyond lysosomal biology by demonstrating it directly drives CD40 ligand expression in T cells, redundantly with TFEB.\",\n      \"evidence\": \"T-cell-specific conditional double knockout mice, EMSA/promoter binding, and reporter assays\",\n      \"pmids\": [\"16936731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define how TFE3 nuclear activity is regulated in T cells\", \"Functional redundancy with TFEB obscures TFE3-specific contributions\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that an oncogenic TFE3 fusion can act through mislocalization, with PSF-TFE3 sequestering wild-type TFE3 and p53 in an extranuclear compartment.\",\n      \"evidence\": \"Subcellular fractionation, immunofluorescence, and siRNA rescue in an endogenous tRCC cell line\",\n      \"pmids\": [\"12902986\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural basis for the abnormal localization\", \"Contrasts with later fusions that are constitutively nuclear, indicating fusion-partner-specific behavior\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked TFE3 to systemic metabolism by identifying IRS-2 as a hepatic target whose activation promotes insulin sensitivity.\",\n      \"evidence\": \"Promoter reporter and transcriptional interaction studies in hepatic models (review of primary work)\",\n      \"pmids\": [\"17279346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review format limits primary-data resolution\", \"Mechanism of Foxo1/SREBP-1c antagonism at the IRS-2 promoter not fully dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a stress-responsive, mTORC1-independent activation route, showing PERK and calcineurin drive TFE3 nuclear entry to upregulate ATF4/UPR genes.\",\n      \"evidence\": \"Pharmacological PERK/calcineurin inhibition with nuclear translocation and reporter assays\",\n      \"pmids\": [\"26813791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosites controlling ER-stress translocation not mapped\", \"Relationship to nutrient-sensing pathway unresolved at this stage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that an oncogenic fusion can paradoxically induce growth arrest, with ASPL-TFE3 transactivating p21 to trigger p53-independent senescence in mesenchymal cells.\",\n      \"evidence\": \"Ectopic and inducible fusion expression, p21 promoter reporter, senescence assays, and p21 siRNA epistasis\",\n      \"pmids\": [\"27673450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependence of arrest vs transformation unexplained\", \"Direct promoter occupancy at endogenous loci not shown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified PI3K/AKT/mTOR pathway genes including IRS-1 as direct fusion targets, linking TFE3 translocation RCC to feed-forward growth signaling.\",\n      \"evidence\": \"TFE3 ChIP-seq in an SFPQ-TFE3 PDX with siRNA knockdown and pathway phospho-readouts\",\n      \"pmids\": [\"30061365\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single PDX model\", \"Causal contribution of each target to tumor growth not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed TFE3 within circadian and developmental signaling networks via direct regulation of Rev-erb\\u03b1 and as a downstream effector of FLCN suppressing WNT signaling.\",\n      \"evidence\": \"TFEB/TFE3 double KO mice with ChIP-seq and behavioral assays; FLCN KO with TCF/LEF reporters and TFE3 rescue\",\n      \"pmids\": [\"31126958\", \"31272105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect mechanism of WNT suppression unclear\", \"TFE3-specific cistrome separable from TFEB only partially defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed cell-cycle and fusion-driven metabolic control: CDK4/6 phosphorylate TFE3 to enforce nuclear export, while PRCC-TFE3 activates PRKN-driven mitophagy and mitochondrial fission programs.\",\n      \"evidence\": \"Reciprocal Co-IP and CDK4/6 perturbation; promoter/ChIP and mitophagy/ROS assays in PRCC-TFE3 tRCC lines\",\n      \"pmids\": [\"32662822\", \"33019842\", \"32339358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CDK4/6 phosphosites on TFE3 not mapped\", \"Drp1/Fis1 regulation lacks mechanistic dissection (Low confidence)\", \"Direct vs indirect fission-gene activation unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a dual, opposing kinase logic (AMPK activating, mTORC1 retaining) and identified PLK4 and additional regulators (NRF-1, NUPR1, VPS41/HOPS) controlling TFE3 abundance and localization.\",\n      \"evidence\": \"In vitro AMPK kinase assays with serine mutants; PLK4 perturbation; NRF-1 ChIP/reporter; NUPR1 proteomics/knockdown; VPS41 patient fibroblasts\",\n      \"pmids\": [\"33734022\", \"35316161\", \"34345304\", \"35462576\", \"33851776\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NUPR1-TFE3 direct interaction not established (Low confidence)\", \"Whether AMPK and PLK4 act on overlapping or distinct sites unclear\", \"Integration of multiple regulators into one kinetic model lacking\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed convergent enhancer-machinery hijacking and metabolic rewiring by fusions: YAP-TFE3 engages the ATAC HAT complex, and NONO-TFE3 directly activates HIF1A to drive glycolysis and angiogenesis.\",\n      \"evidence\": \"Co-IP/MS and integrated ChIP-seq/RNA-seq for YAP-TFE3; ChIP and reporter with metabolic assays for NONO-TFE3\",\n      \"pmids\": [\"33913810\", \"33845743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Fusion-partner-specific cofactor requirements not generalized\", \"Single cell-line models for metabolic readouts\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved the central nutrient-degradation mechanism: Rag-GTPase recruitment activates a conserved phospho-degron for CUL1\\u03b2-TrCP-mediated turnover, with disease variants and translocations both disrupting this control.\",\n      \"evidence\": \"Lysosomal fractionation, ubiquitination assays, RagA Co-IP, degron/helix mutagenesis, and disease-variant validation\",\n      \"pmids\": [\"36608670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase generating the degron phosphorylation not fully defined\", \"How fusion loss of degron quantitatively elevates nuclear TFE3 not measured\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the nuclear transcriptional machinery and stress inputs: FACT chromatin remodeling and KDM6A recruitment are required for output, TRIM28 limits TFE3 levels, eIF2\\u03b1 phosphorylation and TMEM55B-FLCN/FNIP sequestration gate stress translocation, and FLCN licenses mTORC1-dependent phosphorylation in vivo.\",\n      \"evidence\": \"Co-IP, siRNA/curaxin, ubiquitination and histone-mark ChIP; phospho-deficient eIF2\\u03b1 cells; TMEM55B KO zebrafish; Flcn/Tfeb/Tfe3 KO mice and xenograft rescue\",\n      \"pmids\": [\"35230915\", \"36935008\", \"36719671\", \"38168055\", \"36987696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of FACT vs KDM6A recruitment at target promoters unclear\", \"How distinct stress kinases converge on the same translocation machinery not unified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ASPSCR1::TFE3 governs in vivo tumorigenesis through super-enhancer-driven angiogenesis programs rather than autonomous proliferation.\",\n      \"evidence\": \"Inducible fusion depletion, H3K27ac ChIP-seq, CRISPR/dCas9 epigenomic screen, and in vivo tumor models\",\n      \"pmids\": [\"37029109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors organizing the super-enhancers not yet identified at this stage\", \"In vitro vs in vivo dependence discrepancy mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified VCP/p97 as an obligate ASPSCR1::TFE3 cofactor organizing enhancer chromatin, and clarified mTORC1 pool-specific feedback controlling wild-type TFE3 localization.\",\n      \"evidence\": \"Co-IP/MS, ChIP-seq co-occupancy, HiChIP, VCP ATPase mutants, and in vivo epistasis; activated mTOR mutants with lysosomal fractionation\",\n      \"pmids\": [\"38326311\", \"39486419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of distinct mTORC1 pool substrate specificity unresolved\", \"How VCP ATPase activity mechanically organizes enhancer loops not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended fusion biology to dual transcription/splicing activity and cyclin D1-driven proliferation, and established WWTR1::TFE3 transformation as TEAD-binding-dependent.\",\n      \"evidence\": \"FRET dimerization, transcriptome/splicing profiling, PDX validation; ChIP-seq and CDK4/6 inhibition; soft agar assay with TEAD-domain mutagenesis\",\n      \"pmids\": [\"38266162\", \"38657118\", \"38380774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of splicing vs transcription to transformation not quantified\", \"WWTR1::TFE3 in vivo relevance from single case\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a TFE3-fusion-selective metabolic vulnerability (OXPHOS dependence and EGLN1) and a role for TFE3 in driving the mesenchymal/invasive melanoma state downstream of MITF-FLCN/FNIP control.\",\n      \"evidence\": \"Genome-scale CRISPR screen with metabolic flux and EGLN1 inhibition in tRCC; TFE3 deletion and FLCN/FNIP epistasis in MITF-low melanoma\",\n      \"pmids\": [\"39915638\", \"40138313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same OXPHOS rewiring generalizes across fusion partners not fully tested\", \"Melanoma TFE3 target genes driving invasion not enumerated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the multiple upstream kinases (mTORC1, AMPK, CDK4/6, PLK4, PERK/eIF2\\u03b1) and phosphatases are integrated into a single quantitative model of TFE3 phosphosite occupancy that dictates localization, stability, and target-gene selectivity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Complete TFE3 phosphosite map across conditions lacking\", \"Rules determining which target programs (CLEAR vs UPR vs metabolic) are selected not defined\", \"Structural basis of fusion-driven enhancer cofactor recruitment incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 5, 7, 26, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 5, 16, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 3, 13, 14, 23]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3, 14]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [3, 14, 15]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [1, 5, 10, 11, 12, 18, 22, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 7, 16, 26]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 13, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 18, 23, 24, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 8, 14, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 21]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 11, 23, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RagA\", \"VCP\", \"SSRP1\", \"SUPT16H\", \"KDM6A\", \"TRIM28\", \"FLCN\", \"Foxo1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}